Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma.
about
The clinical and economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancerOral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trialsChemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial.Targeting cancers in the gastrointestinal tract: role of capecitabineWhich endpoints should we use in evaluating the use of novel fluoropyrimidine regimens in colorectal cancer?Oral cancer treatment: developments in chemotherapy and beyond.Metastatic colorectal cancer: systemic treatment in the new millennium.Use of capecitabine in management of early colon cancer.Emerging drugs in colorectal cancer.Capecitabine as a radiosensitizing agent in neoadjuvant treatment of locally advanced resectable rectal cancer: prospective phase II trialBeyond 5-fluorouracil: new horizons in systemic therapy for advanced colorectal cancer.Drug Insight: Metastatic colorectal cancer--oral fluoropyrimidines and new perspectives in the adjuvant setting.Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trialA review of the role of capecitabine in the treatment of colorectal cancer.Dihydro pyrimidine dehydrogenase deficiency in patients treated with capecitabine based regimens: a tertiary care centre experience.The effect and clinical efficacy of lienal polypeptide injection combined with FOLFOX chemotherapy regimen in colon cancer patients.Colorectal cancer: current care, future innovations and economic considerations.Should capecitabine replace 5-fluorouracil in the first-line treatment of metastatic colorectal cancer?Delayed Presentation of DPD Deficiency in Colorectal Cancer.Concurrent capecitabine and upper abdominal radiation therapy is well toleratedMulticenter phase II study of oral capecitabine plus irinotecan as first-line chemotherapy in advanced colorectal cancer: a Korean Cancer Study Group trial.A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer.Health-related quality of life and cost comparison of adjuvant capecitabine versus 5-fluorouracil/leucovorin in stage III colorectal cancer patients.A rapid and simple HPTLC assay for therapeutic drug monitoring of capecitabine in colorectal cancer patients.Network meta-analysis of the efficacy of first-line chemotherapy regimens in patients with advanced colorectal cancer.Phase I/II study of bi-weekly XELIRI plus bevacizumab treatment in patients with metastatic colorectal cancer resistant to oxaliplatin-based first-line chemotherapy.Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrent-adjuvant to induction-concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherFactors Impacting Treatment Choice in the First-Line Treatment of Colorectal Cancer.Reply: UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer.A phase II study of capecitabine, irinotecan, and bevacizumab in patients with previously untreated metastatic colorectal cancer
P2860
Q24652904-CAB74B91-69CE-491E-9137-560BC26A6791Q30913489-B02893FF-139F-406E-856F-74FAC6A47346Q33899433-C4CFDD7D-5A69-4954-B7B9-8202C0D73D69Q33916021-A3B939B0-167E-4AB3-9B0A-93A302539106Q34711507-EBB001B8-73EB-4343-A06D-5B36F65D48E7Q34998692-473AA9D9-8562-4928-873A-92AEB185DD8FQ35148795-4A140D8C-AA33-4C68-B78C-33359582525BQ35212953-5274CFAB-6CF0-4F87-8EB8-420A8F938098Q35581170-CE058388-D93B-4C58-AF5E-A66307FF1688Q36147847-F28EBF0F-EFD9-47C8-8BB3-33C46325C957Q36187034-A379F4F5-E5D5-4403-BCF3-6B420DA2F325Q36306269-B300AF27-B4D5-4664-A391-B0FAF8226879Q36614123-B4251922-94DC-4D04-80CE-FAF1556A8D86Q36661290-A6683814-DD1F-40DE-92C2-78B339AB1499Q36936972-1E437CAA-FC3C-41D1-9297-03B60721DDB8Q37406859-0B5EA38B-80A2-493E-96AC-E515C29FA777Q37763182-9C15EC46-45C7-4838-B46A-AEDD33ABB82DQ38216008-3FD31506-F2D5-418A-858E-2DC8AA496611Q38236614-C500D127-079A-4F1F-AC27-8941A549DC16Q39063211-E86DDC98-A4B0-4E18-8116-AA17FCE1FA39Q46632073-DEE7A867-E3B5-4E17-9F45-BDE7E6D1BF11Q46847847-89A021F2-664A-4A5B-BBA9-479A60C1E519Q48069026-508C62DC-3AC8-4466-899C-801187522120Q48305743-B165E6F7-26E1-481E-81BA-CFF00A228F4CQ49805728-3E220BE2-9435-438D-A827-053C2220F6D2Q50998049-297209E5-82CD-4AE3-9AE8-AEA3BFD006B4Q53662723-0707F4C5-EB1E-4387-99B3-85F369E06AD7Q55007703-8945E320-F033-4D4B-83B0-27086AD67E42Q55691415-4EE40991-5CC8-43EB-ABE0-6CBFE11E6B00Q57896517-9D3C242A-E046-409E-9103-D17E4552A3F2
P2860
Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Capecitabine (Xeloda) improves ...... advanced colorectal carcinoma.
@en
type
label
Capecitabine (Xeloda) improves ...... advanced colorectal carcinoma.
@en
prefLabel
Capecitabine (Xeloda) improves ...... advanced colorectal carcinoma.
@en
P2093
P1476
Capecitabine (Xeloda) improves ...... advanced colorectal carcinoma
@en
P2093
B Osterwalder
C Jamieson
Xeloda Colorectal Cancer Study Group
P304
P356
10.1016/S0959-8049(00)00444-5
P50
P577
2001-03-01T00:00:00Z